Takeda S, Nakao A, Ichihara T, Suzuki Y, Nonami T, Harada A, Koshikawa T, Takagi H
Department of Surgery II, I Nagoya University School of Medicine, Japan.
Hepatogastroenterology. 1991 Apr;38(2):143-8.
We studied SPan-1 antigen in 64 patients with pancreatic cancer by measuring serum concentrations with RIABEAD and examining the intratumor staining patterns immunohistochemically. Serum concentrations were elevated (greater than 30 U/ml) in 46 patients (72.0%), roughly the same percentage as with elevated serum CA19-9 concentrations. Ten out of 19 patients without CA19-9 antigen expressed SPan-1, and the combined rate of positivity was 86% (55/64). Immunohistochemically, CA19-9 was localized to the apical surface and the supranuclear cytoplasm of normal epithelial cells, but SPan-1 was localized to the supranuclear cytoplasm or throughout the cytoplasm. After malignant degeneration, both antigens were found over the entire plasma membrane, throughout the cytoplasm (loss of polar distribution) and in the stroma surrounding the cells. SPan-1 was detected in 48 out of 54 adeno-carcinomas of the pancreas (89%), and all cases with an elevated serum concentration displayed stromal staining in the cancer tissues. The utility of SPan-1 antigen as a tumor marker for diagnosing pancreatic cancer was found to be equal to that of CA19-9.
我们通过使用RIABEAD测量血清浓度并免疫组化检查肿瘤内染色模式，对64例胰腺癌患者的SPan-1抗原进行了研究。46例患者（72.0%）的血清浓度升高（大于30 U/ml），这一比例与血清CA19-9浓度升高的比例大致相同。19例无CA19-9抗原的患者中有10例表达SPan-1，阳性合并率为86%（55/64）。免疫组化显示，CA19-9定位于正常上皮细胞的顶端表面和核上细胞质，但SPan-1定位于核上细胞质或整个细胞质。恶性变后，两种抗原均在整个质膜、整个细胞质（极性分布丧失）以及细胞周围的基质中被发现。54例胰腺腺癌中有48例检测到SPan-1（89%），所有血清浓度升高的病例在癌组织中均显示基质染色。发现SPan-1抗原作为胰腺癌诊断肿瘤标志物的效用与CA19-9相当。
